terça-feira, 6 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 27, 2026

Strategy sells $544.5M in MSTR, makes no bitcoin purchase

View original at finance.yahoo.com
Strategy sells $544.5M in MSTR, makes no bitcoin purchase Crypto markets are entering a new phase as institutional adoption accelerates and industry shakeouts continue…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • There are no longer any question marks about Saylor being an irrational actor in the market; the biggest risk to Strategy is duration risk, not price.

    60% confidence

  • Robinhood's approach to prediction markets resembles a dating app, offering anyone's markets, taking a cut, and moving on.

    60% confidence

  • Strategy is no longer just a company that raises cash to buy Bitcoin; it now raises cash for many reasons while managing an entire financial ecosystem built around Bitcoin.

    60% confidence

  • The four crypto business shutdowns/bankruptcies in one week are bottom signals for the market, driven by weak, marginal players being squeezed out rather than technology failure.

    60% confidence

  • The DTCC settles $4.5 quadrillion in volume a year.

    60% confidence

  • Circle's purchase of nearly 1,000 IBM blockchain patents is about building a competitive moat for Circle's Arc and payments network.

    60% confidence

Data points we hold from this source

Strategy · strc repurchase value25 USD
Strategy · cash3.75 USD
Strategy · bitcoin cost basis63.7 USD
Strategy · shares sold5.43 millions
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Strategy sells $544.5M in MSTR, makes no bitcoin purchase — Source | Via News | pt.VIA.NEWS